Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (NASDAQ: COGT) is a pioneering biotechnology company focused on developing precision therapies for genetically defined diseases. Headquartered in Waltham, MA, and Boulder, CO, Cogent's mission is to design rational, targeted therapies that treat the underlying causes of disease, thereby improving the lives of patients. The company's lead program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. This mutation is a key driver of Systemic Mastocytosis (SM) and Advanced Gastrointestinal Stromal Tumors (GIST), both serious diseases dependent on oncogenic KIT signaling.
Bezuclastinib is undergoing rigorous clinical trials, with the PEAK, SUMMIT, and APEX trials all targeted toward specific genetic mutations associated with these diseases. The company has made significant strides in 2024, including the initiation of a new Phase 2 clinical trial of bezuclastinib in later line GIST patients in collaboration with the Sarcoma Alliance for Research through Collaboration (SARC), The Life Raft Group, and Dana-Farber Cancer Institute.
In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies focused on mutations in FGFR2, ErbB2, and PI3Kα. These programs aim to create therapies with potential best-in-class properties, targeting rare and genetically driven diseases.
The company recently secured $225 million in a private investment led by prominent investors, ensuring a robust financial position that supports its ambitious research and development goals. Cogent's financial stability is further reinforced by a strong cash runway projected to extend into 2027, allowing the company to complete its ongoing and planned clinical trials.
Latest News:
- February 26, 2024: Cogent announces a successful $225 million funding round, enhancing its financial stability.
- February 22, 2024: Positive Part 1b data from the ongoing SUMMIT trial evaluating bezuclastinib in NonAdvSM patients.
- February 14, 2024: New Phase 2 clinical trial of bezuclastinib in later line GIST patients announced in collaboration with SARC.
- January 9, 2024: Key milestones for 2024 highlighted at J.P. Morgan’s 42nd Annual Healthcare Conference.
For more detailed and updated information, visit Cogent Biosciences' official website and follow them on social media platforms like X (formerly known as Twitter) and LinkedIn.
Cogent Biosciences announced positive data from its Phase 2 APEX clinical trial of bezuclastinib for advanced systemic mastocytosis (AdvSM). All patients showed ≥50% reduction in serum tryptase, with a median reduction of 89%. Additionally, all assessed patients had ≥50% bone marrow mast cell reduction. The treatment demonstrated a favorable safety profile, with no severe adverse effects reported. Cogent plans to continue enrolling patients and provide further updates by the end of 2022 and in early 2023 for related clinical trials.
Cogent Biosciences will host an investor webcast on June 10, 2022, at 8:00 am ET to discuss initial clinical data from the APEX Phase 2 trial of bezuclastinib in patients with Advanced Systemic Mastocytosis. The presentation will take place during the European Hematology Association Congress, featuring leaders like President & CEO Andrew Robbins and Dr. Daniel J. DeAngelo from Dana-Farber. Interested participants can join via a dial-in number or the company’s website, where an archived version will also be available.
Cogent Biosciences, Inc. (Nasdaq: COGT) has announced that its Annual Meeting of Stockholders is set for June 7, 2022, at 9:00 AM ET, to be held virtually. Shareholders can access pertinent documents, including the agenda, on the company's website. Cogent focuses on precision therapies for genetically defined diseases, notably advancing its clinical program for bezuclastinib, which targets the KIT D816V mutation responsible for systemic mastocytosis. The company is also developing therapies for other serious diseases linked to genetic mutations.
Cogent Biosciences (Nasdaq: COGT) has announced a poster presentation at the European Hematology Association (EHA) Congress, scheduled for June 9-12, 2022. This presentation will highlight the initial results from the ongoing Phase 2 APEX trial assessing the efficacy of bezuclastinib in treating patients with advanced systemic mastocytosis (AdvSM). The abstract is accessible on the EHA website, with the poster set to be published on June 10, 2022. Bezuclastinib is aimed at inhibiting the KIT D816V mutation, a significant contributor to systemic mastocytosis.
Cogent Biosciences has announced initial data from its APEX trial of bezuclastinib, targeting advanced systemic mastocytosis, to be presented at the European Hematology Association 2022 meeting. The company reported a cash balance of $191 million at the end of Q1 2022, sufficient to fund operations into 2024. R&D expenses surged to $25.5 million from $8.2 million year-over-year, while the net loss widened to $30.6 million from $11.7 million. Cogent is progressing multiple clinical trials and research programs, enhancing its oncology pipeline.
Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, announced management's participation in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on May 10, 2022, at 3:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with an archived replay available for 30 days. Cogent's lead program, bezuclastinib, targets the KIT D816V mutation and other KIT exon 17 mutations, which are linked to systemic mastocytosis and gastrointestinal stromal tumors (GIST).
Cogent Biosciences (COGT) presented new nonclinical data for bezuclastinib at the AACR annual meeting, indicating its potential as a best-in-class KIT mutant inhibitor, particularly for systemic mastocytosis and gastrointestinal stromal tumors (GIST). The data highlight its selectivity against related kinases and minimal brain penetration. The company also continues to advance its FGFR2 and ErbB2 inhibitor programs, with plans to file an IND for FGFR2 in the latter half of 2023. Initial APEX trial results are expected later this quarter.
On March 29, 2022, Cogent Biosciences (Nasdaq: COGT) announced a Virtual R&D Investor Event scheduled for April 8, 2022, at 4:05 PM EDT. The event will include updates on nonclinical data for bezuclastinib, a KIT mutant inhibitor, and insights into their strategy for developing small molecules for genetically defined diseases. Featured speakers include Andrew Robbins, John Robinson, and Jessica Sachs. Additionally, Cogent will present two posters at the AACR Annual Meeting 2022, showcasing new data on bezuclastinib and FGFR inhibitors. Registration for the event is available online.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced its financial results for 2021, reporting a net loss of $72.3 million, with R&D expenses rising to $55.9 million due to ongoing clinical trials for its drug bezuclastinib. The company ended the year with $219.7 million in cash, projected to sustain operations through 2024. Currently, Cogent is actively enrolling patients in three late-stage bezuclastinib trials: APEX, SUMMIT, and PEAK. Initial data from the APEX trial is expected in the first half of 2022, alongside an R&D Investor Event scheduled for April 8, 2022.
Cogent Biosciences (Nasdaq: COGT) announced the upcoming presentation of two abstracts at the AACR Annual Meeting, taking place from April 8-13, 2022, in New Orleans, Louisiana. The presentations will focus on the unique properties of bezuclastinib, a selective KIT inhibitor, and a novel series of FGFR2 inhibitors. The first poster highlights nonclinical data showcasing bezuclastinib's differentiation from other KIT inhibitors, while the second explores the potency of FGFR inhibitors against mutations. Both presentations are scheduled for April 10, 2022.
FAQ
What is the current stock price of Cogent Biosciences (COGT)?
What is the market cap of Cogent Biosciences (COGT)?
What does Cogent Biosciences, Inc. specialize in?
What is the main clinical program of Cogent Biosciences?
Where is Cogent Biosciences headquartered?
What recent achievements has Cogent Biosciences accomplished?
What are the financial prospects of Cogent Biosciences?
What other programs is Cogent developing besides bezuclastinib?
How can I stay updated with Cogent Biosciences' latest news?
What are Cogent Biosciences' key clinical trials?
Who are Cogent Biosciences' key collaborators?
How does bezuclastinib work?
